key: cord-0843527-b5bf75q4 authors: Best, Jennie H.; Kong, Amanda M.; Kaplan‐Lewis, Emma; Brawley, Otis W.; Baden, Rachel; Zazzali, James L.; Miller, Karen S.; Loveless, James; Jariwala‐Parikh, Krutika; Mohan, Shalini V. title: Treatment patterns in US patients hospitalized with COVID‐19 and pulmonary involvement date: 2021-05-31 journal: J Med Virol DOI: 10.1002/jmv.27049 sha: de497207f87ac64ba3b3f0f8f87e4141fe3cd66c doc_id: 843527 cord_uid: b5bf75q4 This study describes the baseline characteristics and treatment patterns of US patients hospitalized with a diagnosis of coronavirus disease 2019 (COVID‐19) and pulmonary involvement. Patients hospitalized with pulmonary involvement due to COVID‐19 (first hospitalization) were identified in the IBM Explorys® electronic health records database. Demographics, baseline clinical characteristics, and in‐hospital medications were assessed. For evaluation of in‐hospital medications, results were stratified by race, geographic region, age, and month of admission. Of 6564 hospitalized patients with COVID‐19‐related pulmonary involvement, 50.4% were male, and mean (SD) age was 62.6 (16.4) years; 75.2% and 23.6% of patients were from the South and Midwest, respectively, and 50.2% of patients were African American. Compared with African American patients, a numerically higher proportion of White patients received dexamethasone (19.7% vs. 31.8%, respectively), nonsteroidal anti‐inflammatory drugs (NSAIDs; 27.1% vs. 34.9%), bronchodilators (19.8% vs. 29.5%), and remdesivir (9.3% vs. 21.0%). Numerically higher proportions of White patients than African American patients received select medications in the South but not in the Midwest. Compared with patients in the South, a numerically higher proportion of patients in the Midwest received dexamethasone (20.1% vs. 34.5%, respectively), NSAIDs (19.6% vs. 55.7%), bronchodilators (15.9% vs. 41.3%), and remdesivir (10.6% vs. 23.1%). Inpatient use of hydroxychloroquine decreased over time, whereas the use of dexamethasone and remdesivir increased over time. Among US patients predominantly from the South and Midwest hospitalized with COVID‐19 and pulmonary involvement, differences were seen in medication use between different races, geographic regions, and months of hospitalization. for patients with COVID-19, were included (Table S1 ). If a patient had multiple hospitalizations for COVID-19 with pulmonary involvement, only the first hospitalization was analyzed. Overall, the most common inpatient medications were corticosteroids (including dexamethasone and methylprednisolone; 31.3%), nonsteroidal anti-inflammatory drugs (NSAIDs; 28.2%), bronchodilators (22.1%), hydroxychloroquine (19.6%), and remdesivir (13.5%; However, insurance coverage is unlikely to account for differences in use of a low-cost therapy, such as dexamethasone. Also, inpatient care (including medications) is reimbursed based on diagnosisrelated group codes, so costs may not be a major factor in deciding whether patients receive a particular therapy. Although exploring all the possible reasons for regional differences in medication use by race is beyond the scope of this manuscript, these results raise important questions and warrant further study. Within this population of patients predominantly from the Midwest and South, we found regional differences in the use of medications. Differences in the patterns of prescriptions may reflect varying treatment guidelines and implementation of evidence-based medicine and differences in practice between hospitals and healthcare systems across regions, and variable access to medications and healthcare resources due to regional surges in COVID-19-related hospitalizations. Further study is warranted with regard to regional differences and potential resulting health outcome disparities. This study demonstrated notable changes in medication use in patients with COVID-19 and pulmonary involvement over a relatively short period of time. Hydroxychloroquine and chloroquine are approved to treat or prevent malaria, and hydroxychloroquine is approved to treat certain autoimmune conditions, including rheumatoid arthritis and systemic lupus erythematosus, due to their immunomodulatory effects. 19 The US Food and Drug Administration Most patients in this study were from the South and Midwest, and our results may not be generalizable to the overall US population. However, because the selection criteria included nationally used ICD codes, the selection of these populations was unintentional and likely reflects the geographic distribution of the Explorys database and the pandemic outbreak itself. As the treatment of patients with COVID-19 is evolving in this rapidly changing and unprecedented pandemic environment, it is possible that treatment patterns have changed over time by region and race, and these potential trends were not evaluated. In part due to this ever-changing The novel coronavirus originating in Wuhan, China: challenges for global health governance First case of 2019 novel coronavirus in the United States Trends in number and distribution of Covid-19 hotspot counties -United States Coronavirus COVID-19 global cases Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 Cases From the Chinese Center for Disease Control and Prevention COVID-19 diagnosis and management: a comprehensive review SARS-CoV-2 infection: the role of cytokines in COVID-19 disease Coronavirus Disease Factors associated with death in critically ill patients with coronavirus disease 2019 in the US Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 -COVID-NET, 14 states Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit The impact of ethnicity on clinical outcomes in COVID-19: a systematic review Hospitalization and mortality among black patients and white patients with Covid-19 Assessment of COVID-19 hospitalizations by race/ethnicity in 12 states The disproportionate effect of COVID-19 mortality on ethnic minorities: genetics or health inequalities? ICD-10-CM official coding guidelines-supplement coding encounters related to COVID-19 coronavirus outbreak effective Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases United States Population Estimates v2019 Hydroxychloroquine: from malaria to autoimmunity Remdesivir for the treatment of Covid-19 -final report Dexamethasone in hospitalized patients with Covid-19 -preliminary report This was a retrospective, observational study, and all study data were deidentified and fully compliant with Health Insurance Portability and Accountability Act regulations (45 CFR 164.514e); therefore, approval from an Institutional Review Board was not required, and informed consent was not obtained.